Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study by Chen, Y et al.
RESEARCH ARTICLE Open Access
Interaction between smoking and functional
polymorphism in the TGFB1 gene is associated
with ischaemic heart disease and myocardial
infarction in patients with rheumatoid arthritis: a
cross-sectional study
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Abstract
Introduction: Transforming growth factor-beta1 (TGF-beta1) is a pleiotropic cytokine that plays important roles in
immunity and inflammation. Some studies have suggested that polymorphism in the TGFB1 gene is associated
with heart disease in the general population. The purpose of the present study was to determine whether
common single-nucleotide polymorphisms (SNP) in the TGFB1 gene are associated with ischaemic heart disease
(IHD) and/or myocardial infarction (MI) in patients with rheumatoid arthritis (RA), and to investigate the influence of
smoking on any association.
Methods: PCR-based assays were used to determine the genotypes of TGFB1 SNPs including TGFB1-509 C/T
(rs1800469, in the promoter region), +868 T/C (rs1800470, in exon 1) and +913 G/C (rs1800471, in exon 1) in 414
subjects with established RA. Genotyping for the +868 SNP was also carried out on a second study population of
RA patients (n = 259) with early disease. Serum levels of TGF-beta1 were measured using a commercial ELISA kit.
Smoking history and IHD/MI status were obtained on each patient. Associations with IHD/MI were assessed using
contingency tables and logistic regression analyses.
Results: The heterozygous genotype of TGFB+868 was associated with an increased risk of IHD (OR 2.14, 95% CI
1.30 - 3.55) and MI (OR 2.42, 95% CI 1.30-4.50), compared to the homozygous genotypes combined. Smoking was
an independent risk for IHD and MI, and evidence of interaction between smoking and TGFB+868 was found.
Multivariate analyses indicated that the strongest associations with IHD and MI were due to the combined effect of
the TGFB1+868 TC genotype and smoking (OR 2.75, 95% CI 1.59-4.75; and OR 2.58 95% CI 1.33-4.99, respectively),
independent of other cardiovascular risk factors. The association of the +868 TC genotype and evidence of +868
TC-smoking interaction with IHD were replicated in a second population of RA patients with early disease. Serum
TGF-beta1 levels were not associated with TGFB1 genetic variations, smoking or IHD/MI status.
Conclusions: Interaction between smoking and polymorphism in the TGFB1 gene may influence the risk of IHD
and MI in patients with RA.
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Introduction
The excess risk of cardiovascular disease (CVD) asso-
ciated with rheumatoid arthritis (RA) has long been
recognized [1-4]. Among cardiovascular (CV) condi-
tions, ischaemic heart disease (IHD), usually due to cor-
onary artery disease (CAD), is the most common
comorbidity in RA. A higher incidence of CAD in
patients with RA in comparison with control subjects
has been reported, and patients with RA are more likely
to experience unrecognized myocardial infarction (MI)
and sudden death [5]. Other studies have suggested that
the increase of CV events in RA is due mainly to an
excess of MI [6,7]. A number of risk factors for the
development of CVD in RA have been established and
these include classic risks such as smoking, hyperten-
sion, insulin resistance, body composition alterations,
and RA characteristics such as autoantibodies, extra-
articular disease, and increased inflammatory burden
[1,2].
The genetic predisposition to CVD in RA has been the
subject of an increasing number of studies in recent
years. We and others have shown that certain HLA-
DRB1 shared epitope alleles are associated with
endothelial dysfunction and with the increased risk of
CV events/mortality in RA [8-11]. Polymorphism in
other genes in the HLA region, namely lymphotoxin A
and tumor necrosis factor-alpha (TNFA) -308, has also
been shown to be associated with CVD in RA [12,13].
Several polymorphisms in non-HLA genes have also
been reported to be associated with CV conditions/
events in RA [14-19].
Transforming growth factor-beta-1 (TGF-b1) is a mul-
tifunctional cytokine that plays an important role in a
range of biological processes, including the modulation
of immunity and inflammation, control of cellular prolif-
eration, migration and differentiation, and regulation of
tissue repair and extracellular matrix accumulation. In
RA, it has been reported that TGF-b1 is produced in
the synovial tissue and that enhanced expression of this
cytokine is associated with remission of disease [20,21].
Furthermore, an animal model of arthritis revealed a
relationship between TGF-b1 overexpression and disease
reduction [22]. The role of TGF-b1 in the pathogenesis
of atherosclerosis has long been the subject of debate.
Inhibition of endogenous TGF-b signaling favors the
development of atherosclerotic lesions [23], but a
proatherogenic role of TGF-b1 is also suspected since it
is able to promote fibrosis and to inhibit endothelial
regeneration [24].
The TGFB1 gene is located on the long arm of chro-
mosome 19 at position 13.2. Cambien and colleagues
[25] described the common polymorphisms in Cauca-
sians: -800 G/A (rs1800468) and -509 C/T (rs1800469)
in the promoter region, a C insertion at position +72 in
the non-translated region, +868 T/C (rs1800470) and
+913 G/C (rs1800471) in exon 1, and +11929 C/T
(rs1800472) in exon 5. Polymorphism in the TGFB1
gene has been associated with certain CV conditions
(mainly MI) with different disease-associated single-
nucleotide polymorphisms (SNPs) (-509, +868, and/or
+913) in different studies [25-29]. However, other stu-
dies have reported no association [30-33]. An associa-
tion between the TGFB1+868 SNP and hypertension has
been demonstrated in RA [34], and we have reported an
association of this SNP with mortality in RA [35]. To
investigate the possible role of the TGFB1 gene in the
development of IHD in RA, we have examined the asso-
ciation of selected SNPs (-509, +868, and +913) with the
presence of IHD or previous MI in a cohort of patients
recruited into a study of comorbidity in RA. The rela-
tionship between TGFB1 polymorphism and the circu-
lating level of TGF-b1 was also investigated, as was the
possibility of an interaction between smoking and the
TGFB1 gene.
Materials and methods
Patients
This study was based on a cohort (n = 430) of patients
who were consecutively recruited, were white Northern
Europeans, had RA, and were residents of North Staf-
fordshire, England. All patients had a diagnosis of RA
and met the 1987 American College of Rheumatology
criteria [36]. Written informed consent was provided by
each patient in accordance with the Declaration of Hel-
sinki. The research was approved by the North Stafford-
shire local research ethics committee. Sixteen (3.7%)
samples were excluded from this report on the grounds
that genotyping data or information about cigarette
smoking was incomplete. Inclusion or exclusion of these
samples made no significant difference to the associa-
tions found.
Most patients (93.5%) had been treated with one or
more disease-modifying anti-rheumatic drugs
(DMARDs). The majority were being treated with meth-
otrexate (MTX), sulfasalazine (SSZ), or hydroxychloro-
quine. The commonest combination therapy of DMARD
was MTX and SSZ. A small proportion of patients were
being treated with steroids (9.7%) or cytotoxic drugs
such as azathioprine or cyclophospamide (< 5%). Some
patients (14.5%) were on a biologic agent (mainly eta-
nercept and infliximab) at the time of recruitment.
Demographic data, including gender, age, weight,
height, and occupation, were obtained for each patient.
A core set of clinical and laboratory-based RA charac-
teristics was recorded at recruitment. This included age
at RA onset, disease duration, IgM rheumatoid factor
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(RF), anti-cyclic citrullinated peptide antibody, levels of
C-reactive protein (CRP) and erythrocyte sedimentation
rate, the Disease Activity Score using 28 joint counts
(DAS28) [37], the Health Assessment Questionnaire
[38], and the presence/absence of erosive and nodular
disease. Information on current or past cigarette smok-
ing was obtained from a questionnaire completed by
each patient at recruitment, as described previously [17].
Evidence of cardiovascular disease (IHD, previous MI,
heart failure, and so on) was obtained from a structured
interview, review of the medical notes, and an inventory
of current and cumulative medication. Furthermore, all
patients underwent resting 12-lead electrocardiography
(ECG). A diagnosis of IHD was based on the presence
of angina pectoris, previous MI (physician-diagnosed) or
evidence of CAD on the basis of angiography, functional
testing, or previous revascularization procedures such as
coronary artery bypass grafting. ECG was further used
to identify possible unrecognized previous MI, as
described previously [17]. Evidence of hypertension,
hypercholesterolemia, and diabetes (type I and II) was
obtained in a previous study on this cohort [17].
A second study population of patients with RA (n = 259,
median age of 55.0 years) with early disease (median dis-
ease duration of 12 months) was used in a replication
study of the association of TGFB1 polymorphism with
IHD. Only patients with diagnosed definite RA (deter-
mined in follow-up in some cases) were included. In this
cohort, the presence of IHD was determined by a struc-
tured interview and review of the medical notes. ECG mea-
surements were not carried out in this group of patients.
TGFB1 SNP typing
Leukocyte DNA was isolated from peripheral blood
samples by using a Nucleon DNA extraction kit (GE
Healthcare, Chalfont St Giles, Buckinghamshire, UK) in
accordance with the instructions of the manufacturer.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis was applied to
determine the genotypes of the TGFB1-509 SNP, and
allelic-specific PCR systems were used to assess the gen-
otypes of the TGFB1+868 and +913 polymorphisms.
The genotyping methods for -509 and +868/+913 were
described previously in [39] and [40], respectively. All
primers were obtained from Sigma-Genosys (Haverhill,
Suffolk, UK), and restriction enzyme was obtained from
New England Biolabs (Hitchin, Hertfordshire, UK). All
PCR amplification reactions were performed in a Flexi-
gene thermal cycler (Techne (Cambridge) Limited, Cam-
bridge, UK) by using a 96-well heating block.
Quantification of circulating TGF-b1 level
Measurement of circulating TGF-b1 was performed on
the serum samples by using a Duoset Human TGF-b1
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN, USA) and was read on a
TiterTek Multiskan Plus MKII microplate reader (Flow
Laboratories Ltd., Rickmansworth, Hertfordshire, UK).
This assay measures the total TGF-b1 present (that is,
the latent acid-activated molecule and any free, active
TGF-b1). Sample and solution preparations and assay
procedure were followed in accordance with the recom-
mendations of the manufacturer.
Statistical analysis
The relationship between TGFB1 genotypes and IHD/
MI was initially analyzed by using contingency tables.
Chi-squared P values are shown unadjusted and
adjusted for multiple testing using the Bonferroni proce-
dure. Meta-analysis was carried out by using MetaP [41]
on the discovery and replication datasets (established
and early RA, respectively). This combines the statistical
association signals (P values) from independent study
populations and takes into account the impacts of sam-
ple sizes and effect directions. A weighted Z-method
(Stouffer’s Z trend) was used to estimate the combined
P value [42]. Multivariate logistic regression analysis was
applied to investigate the independence of novel associa-
tions and to adjust for other possible confounders such
as age, sex, hypertension, and diabetes. Evidence of
interaction between smoking (ever-smoking) and TGFB1
polymorphism was assessed by examining for evidence
of departure from additivity by using the methods of
Rothman and Greenland [43]. By means of this
approach, the attributable proportion due to interaction
(AP) was calculated, together with 95% confidence inter-
val (CI), as detailed by Andersson and colleagues [44].
The AP refers to the attributable proportion of disease
that is due to interaction among individuals with both
exposures. In the case of no biological interaction, AP
equals 0, whereas an AP of 1.0 corresponds to complete
additive interaction. This method has been suggested to
be the most robust when using odds ratios (ORs) in
place of relative risks [45].
By means of Haploview (version 4.2) [46], Hardy-
Weinberg equilibrium (HWE) for the genotypic distribu-
tions of each polymorphism was tested with the chi-
squared goodness-of-fit test. LD coefficient D’ [47] and
r2 were used to estimate the strength of LD and allelic
correlation between each pair of polymorphisms, respec-
tively. The haplotype frequencies were estimated by
using an expectation-maximization algorithm to deter-
mine the maximum-likelihood frequencies of multi-
locus haplotypes [48]. Haplotypic association of TGFB1
genetic variation with serum TGF-b1 levels was investi-
gated under regression-based models in HAPSTAT (ver-
sion 3.0; Department of Biostatistics, University of North
Carolina at Chapel Hill, NC, USA) [49].
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Power calculations were performed by using an online
power calculator [50]. As an example, for SNP TGFB1
+868 (rs1800470), the study had 80% power to detect
ORs of 1.7 or 2.6 for association of the risk allele with
IHD at the 0.05 significance level, assuming recessive or
dominant modes of inheritance, respectively. Multivari-
ate logistic regression analyses were carried out by using
the Number Cruncher Statistical System for Windows
(NCSS 2000) (for stepwise selection analysis) or Stata
(version 8.0) (for obtaining the covariance matrix for
calculation of 95% CI for AP). The significance level was
set at a P value of 0.05.
Results
Characteristics of patients with established RA
The characteristics of patients are displayed in Table 1.
Evidence of IHD and previous MI was found in 20.8%
and 12.6% of patients, respectively. Of the 52 patients
with MI, 13 were identified on the basis of their ECG
(Q-wave development in the absence of any conduction
defect, suggesting full-thickness MI) in addition to the
previously known cases. Patients with IHD or MI were
older and were more likely to be male. No significant
difference in disease duration between patients with or
without IHD/MI was found.
Distributions of the TGFB1 SNP
Genotypes of the three SNPs were determined in 414
patients. The frequencies of TGFB1 genotypes were
49.3% (-509 CC), 44.2% (CT), and 6.5% (TT); 40.8%
(+868 TT), 45.4% (TC), and 13.8% (CC); and 86.0%
(+913 GG), 13.5% (GC), and 0.5% (CC). Genotypes of
these polymorphisms were all distributed in accordance
with a close fit to HWE. The allelic frequencies are
shown in Additional Figure S1 of Additional file 1.
These polymorphisms were strongly linked with each
other, forming two major haplotypes - C-T-G (fre-
quency 63.4%) and T-C-G (28.1%) - across the region.
Serum TGF-b1 level
Serum TGF-b1 levels were determined in 399 (96.4%)
patients and ranged from 183.2 to 48,360 pg/mL. The
Table 1 Selected demographic and clinical characteristics of rheumatoid arthritis patients stratified by the presence of
ischaemic heart disease
Variable All patients
(n = 414)
Patients without IHD (n = 328) Patients with IHD (n = 86) P valuea
Age, years 62.0 (54.8-69.0) 61.0 (54.0-68.0) 67.0 (58.0-72.3) < 0.0001
Age of onset, years 50.0 (41.0-58.0) 49.0 (40.0-56.2) 54.9 (44.3-63.2) 0.0022
Duration, years 10.0 (3.6-18.0) 10.0 (3.0-18.0) 8.0 (4.0-18.0) NS
Male/female 136/278 91/237 45/41 < 0.0001
Body mass index 27.3 (24.6-30.4) 27.3 (24.4-30.3) 27.4 (25.4-31.0) NS
Rheumatoid factor 236/412 (57.3%) 178/326 (54.6%) 58/86 (67.4%) 0.032
Anti-CCP 305/402 (75.9%) 243/320 (75.9%) 62/82 (75.6%) NS
ESR 20 (10-37) 18 (10-34) 26 (10-43.5) NS
CRP (≥ 10 mg/L) 223/414 (53.9%) 162/328 (49.4%) 61/86 (70.9%) 0.0004
Nodules 54/414 (13.0%) 41/328 (12.5%) 13/86 (15.1%) NS
Erosions 301/407 (74.0%) 243/322 (75.5%) 58/85 (68.2%) NS
DAS28b 4.2 (1.4%) 4.1 (1.4%) 4.4 (1.4%) NS
HAQ score 1.6 (1.0-2.0) 1.6 (0.9-2.0) 1.8 (1.3-2.3) 0.014
Ever-smoker 276/414 (66.7%) 205/328 (62.5%) 71/86 (82.6%) 0.0004
Current smoker 74/414 (17.9%) 58/328 (17.7%) 16/86 (18.6%) NS
Previous MI 52/414 (12.6%) - 52/86 (60.5%) -
Hypertension 161/413 (39.0%) 110/327 (33.6%) 51/86 (59.3%) < 0.0001
Hypercholesterolemia 68/414 (16.4%) 39/328 (11.9%) 29/86 (33.7%) < 0.0001
Diabetes (I and II) 30/414 (7.3%) 13/328 (4.0%) 17/86 (19.8%) < 0.0001
DMARD use 386/413 (93.5%) 306/327 (93.6%) 80/86 (93.0%) NS
Methotrexate use 242/413 (58.6%) 204/327 (62.4%) 38/86 (44.2%) 0.0023
Steroid use 40/413 (9.7%) 28/327 (8.6%) 12/86 (14.0%) NS
Biologic agent use 60/413 (14.5%) 53/327 (16.2%) 7/86 (8.1%) NS
Serum TGF-b1 level, pg/mL 16,908 (12,744-21,428) 16,764 (12,422-21,772) 17,156 (13,435-20,533) NS
Values other than P values are presented as number (percentage) or median (interquartile range). aP values show significant differences between patients with
and those without IHD (unadjusted); bmean (standard deviation). Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score
using 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IHD, ischemic
heart disease; MI, myocardial infarction; NS, non-significant; TGF-b1, transforming growth factor-beta-1.
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median (interquartile range) value was 16,908 pg/mL
(12,744 to 21,428 pg/mL). Serum levels of TGF-b1 in
each genotypic group of the studied TGFB1 polymorph-
isms are shown in Figure 1. These polymorphisms were
not associated with serum TGF-b1 levels. Haplotype
analysis indicated that no haplotype across these SNPs
was associated with serum levels. The relationship of
serum TGF-b1 levels with smoking and IHD/MI status
was also investigated, but no significant associations
were observed.
Association of TGFB1 SNP with IHD and MI
The relationship between TGFB1 genotypes and the
presence of IHD/MI, without adjustment for confoun-
ders, is shown in Table 2. There was no association
between TGFB1-509 or TGFB1+913 genotypes and the
presence of IHD/MI. In the case of TGFB1+868, the
distribution of the data did not fit an additive, domi-
nant, or recessive model for association with IHD, but
a significantly increased risk was found for the hetero-
zygous genotype compared with the two homozygous
genotypes combined (Table 2). The heterozygous geno-
type also demonstrated an increased risk compared
with each homozygous genotype individually (TC ver-
sus CC, OR = 2.52, 95% CI 1.10 to 5.79, P = 0.02, and
TC versus TT, OR = 1.86, 95% CI 1.11 to 3.11, P =
0.02). An association of the +868 TC heterozygote
with MI was also found, although an alternative domi-
nant association of the T allele (TT + TC versus CC)
could also be demonstrated. The association of the
+868 TC heterozygote with IHD and MI remained sig-
nificant after adjustment for multiple testing, although
the association of the T allele with MI lost signifi-
cance. Adjustment for age and sex in logistic regres-
sion analyses made little or no difference to the
associations found (data not shown). No significant
haplotypic association of TGFB1 SNP with IHD/MI
was found.
Since there is strong LD between TGFB1-509 and
+868, the weaker signal from -509 may be due to the
greater association of +868 with IHD and MI. This was
supported by logistic regression analysis that contained
both -509 (CT versus CC + TT) and +868 (TC versus
TT + CC) together as independent variables and used
forward stepwise selection to test for the primary risk
factor. The associations involving TGFB1+868 main-
tained significance in relation to both IHD (OR = 2.14,
95% CI 1.30 to 3.55, P = 0.008) and MI (OR = 2.42,
95% CI 1.30 to 4.50, P = 0.007), whereas the association
involving -509 disappeared in these models (adjusted for
age and sex).
Replication of association of the +868 TC genotype with
IHD in patients with early RA
The association of the +868 SNP with IHD was exam-
ined in a second population of patients with early dis-
ease. Evidence of IHD was recorded in 27 out of 259
patients (10.4%). These patients were older (64.0 versus
54.0, P = 0.001) but had a disease duration (10 versus
12.0 months) similar to those without IHD and were
more likely to be male (21.1% versus 12.3%, P = 0.06)
and to have ever smoked (19.1% versus 10.6%, P = 0.1),
although the differences were not significant. As in the
cohort with established disease, the +868 TC heterozy-
gote showed a significant association with IHD when
compared with the homozygous genotypes combined
(Table 3). Combining P values in a meta-analysis of the
+868 TC association with IHD in the patients with
established and early RA demonstrated a significant
association (Stouffer’s Z trend = 0.0003).
Figure 1 Serum transforming growth factor-beta-1 (TGF-b1) levels stratified by TGFB1 single-nucleotide polymorphism (SNP)
genotypes in patients with rheumatoid arthritis (RA). The boxplots show the median and interquartile range, and whiskers represent the 5th
and 95th percentiles. Serum levels were determined in 399 subjects.
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Association of TGFB1-smoking interaction with IHD and
MI
Analysis was also carried out to investigate whether
there was potential interaction of TGFB1 polymorphism
with smoking relative to the occurrence of IHD/MI.
Table 4 shows the occurrence of IHD and MI stratified
by the combination of a TGFB1 heterozygous genotype
(-509 CT and +868 TC) with ever having smoked. Evi-
dence of interaction was tested on the basis of AP with
95% CI. For TGFB1-509, the values of AP (95% CI)
demonstrated only non-significant results, although a
borderline level was seen in relation to IHD. In contrast,
for +868, AP showed a large proportion of effect due to
interaction in relation to both IHD and MI, and the
95% CI indicated the significance of these results.
Alternative models looking at the interaction between
smoking and the -509 C allele or +868 T allele did not
show evidence of significant interaction.
Comparison within non-smokers suggested that the
heterozygous genotypes of the TGFB1 gene alone had
little effect on the risk for IHD and MI. However,
patients who carried the heterozygous genotype and had
ever smoked were at the highest risk for IHD and MI.
The risk was significantly higher compared with that
among patients who had ever smoked but did not carry
these genotypes (for TGFB1+868 SNP in relation to
IHD; smoke+/TC+ versus smoke+/TC-, OR = 2.57, 95%
CI 1.48 to 4.47, P = 0.007; in relation to MI, OR = 2.42,
95% CI 1.26 to 4.67, P = 0.007).
Replication of association of TGFB1+868-smoking
interaction with IHD
An association of the +868 TC genotype with IHD in
patients who had ever smoked but not in non-smokers
was found in a separate population of patients with
early RA (Table 5). Smoking status was available for 222
out of 259 patients in this RA cohort. As in established
RA, the association with IHD in smokers was found
only in patients who carried the TGFB1+868 TC geno-
type (smoke+/TC+ versus smoke+/TC-, OR = 3.55, 95%
CI 1.18 to 10.67, P = 0.025). This was similar to the
association seen when patients with the +868 TC/smok-
ing combination were compared with all of the remain-
ing patients (OR = 3.57, 95% CI 1.47 to 8.69, P = 0.003).
Table 3 Replication study: frequency of ischaemic heart
disease in a second population of early rheumatoid
arthritis patients stratified by TGFB1+868 SNP genotypes
Ischemic heart disease
TGFB1+868 (T/C) Negative Positive
TT 82 (93.2%) 6 (6.8%)
TC 118 (85.5%) 20 (14.5%)
CC 32 (97.0%) 1 (3.0%)
TT + TC versus CC OR = 2.86, 95% CI 0.53-5.46
TC versus TT + CC OR = 2.64, 95% CI 1.10-6.34a
’Negative’ and ‘positive’ values are presented as number (percentage). aP =
0.022. CI, confidence interval; OR, odds ratio; SNP, single-nucleotide
polymorphism; TGFB1, transforming growth factor-beta-1.
Table 2 Frequency of ischaemic heart disease and myocardial infarction in rheumatoid arthritis patients stratified by
TGFB1 SNP genotypes
Ischemic heart disease Myocardial infarction
Negative Positive Negative Positive
TGFB1-509 (C/T)
CC 165 (79.9%) 39 (19.1%) 181 (88.7%) 23 (11.3%)
CT 139 (76.0%) 44 (24.0%) 155 (84.7%) 28 (15.3%)
TT 24 (88.9%) 3 (11.1%) 26 (96.3%) 1 (3.7%)
CC + CT versus TT OR = 1.92, 95% CI 0.61-6.04 OR = 2.70, 95% CI 0.51-14.38
CT versus CC + TT OR = 1.42, 95% CI 0.89-2.28 OR = 1.55, 95% CI 0.87-2.77
TGFB1+868 (T/C)
TT 141 (83.4%) 28 (16.6%) 151 (89.3%) 18 (10.7%)
TC 137 (72.9%) 51 (27.1%) 155 (82.4%) 33 (17.6%)
CC 50 (87.7%) 7 (12.3%) 56 (98.2%) 1 (1.8%)
TT + TC versus CC OR = 1.92, 95% CI 0.85-4.30 OR = 6.32, 95% CI 1.22-32.89a
TC versus TT + CC OR = 2.02, 95% CI 1.25-3.27b OR = 2.29, 95% CI 1.26-4.16c
TGFB1+913 (G/C)
GG 284 (79.8%) 72 (20.2%) 309 (86.8%) 47 (13.2%)
GC 42 (75.0%) 14 (25.0%) 51 (91.1%) 5 (8.9%)
CC 2 (100.0%) 0 (0.0%) 2 (100.0%) 0 (0.0%)
GG versus GC + CC OR = 0.78, 95% CI 0.41-1.49 OR = 1.49, 95% CI 0.59-3.78
’Negative’ and ‘positive’ values are presented as number (percentage). aP = 0.008, Padj = 0.072;
bP = 0.0037, Padj = 0.033;
cP = 0.005, Padj = 0.045. Padj are P values
that have been adjusted for multiple testing (nine possible models) by using the Bonferroni procedure. CI, confidence interval; OR, odds ratio; SNP, single-
nucleotide polymorphism; TGFB1, transforming growth factor-beta-1.
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Combining P values in a meta-analysis of the association
of the +868 TC/smoking combination with IHD in the
patients with established and early RA demonstrated a
highly significant association (Stouffer’s Z trend = 3.79
× 10-7).
Multivariate associations with IHD and MI
We carried out multivariate logistic regression analysis
by using models containing the TGFB1+868 TC-smok-
ing interaction term as well as other known demo-
graphic and clinical risk factors. The multivariate
association models obtained from forward selection ana-
lyses are shown in Table 6. Independent risk factors sig-
nificantly associated with IHD included TGFB1+868
TC-smoking interaction, older age, male sex, CRP of at
least 10 mg/L, hypercholesterolemia, and diabetes,
whereas those associated with MI were TGFB1+868 TC-
smoking interaction, male sex, CRP of at least 10 mg/L,
RF+ (borderline association), hypertension, and hyperch-
olesterolemia. Confirmation of the TGFB1+868 TC-
smoking interaction with IHD independent of other risk
factors was demonstrated in a separate population of
patients with early RA (Table S1 of Additional file 2).
Previously, using the same established RA cohort, we
demonstrated that VEGFA-2578 A allele-smoking inter-
action was associated with an increased risk of IHD and
MI [17]. The addition of the VEGFA-smoking interac-
tion term into the above multivariate models demon-
strated independent associations of both gene-smoking
interaction combinations with IHD and MI (Table S2 of
Additional file 3).
Discussion
To our knowledge, this is the first study to investigate
the involvement of the TGFB1 gene in the risk of CVD
in patients with RA. The results have demonstrated an
association of genetic variation in the TGFB1 gene with
the occurrence of IHD, and MI in particular, and have
further indicated a gene-smoking interaction relative to
the association found. Similar results were found in RA
populations with well-established and early disease.
According to univariate analyses, the TGFB1+868 SNP
was associated with IHD and MI, and the -509 poly-
morphism showed a similar, though not significant, rela-
tionship. Multivariate logistic regression models
containing both SNPs suggest that the trend involving
-509 is not independent of +868 and may be due to LD.
The +913 SNP was apparently neutral since it did not
contribute measurable effects. These results are in line
with those of Crobu and colleagues [27], who investi-
gated the association of TGFB1 SNP with MI in young
Italian patients. By means of univariate analysis only, the
study showed that both -509 and +868 polymorphisms
were associated with MI and that the stronger associa-
tion occurred at position +868. Koch and colleagues
Table 4 Association of TGFB1 heterozygous genotypes with ischaemic heart disease and myocardial infarction in
rheumatoid arthritis patients stratified by ever smoking
Ischemic heart disease Myocardial infarction
Negative Positive OR (95% CI) Negative Positive OR (95% CI)
Smoke/-509 CT
-/- 65 (89.0%) 8 (11.0%) 1.0 (referent) 70 (95.9%) 3 (4.1%) 1.0 (referent)
-/+ 58 (89.2%) 7 (10.8%) 0.99 (0.35-2.80) 61 (93.8%) 4 (6.2%) 1.47 (0.35-6.21)
+/- 124 (78.5%) 34 (21.5%) 2.14 (0.95-4.79) 137 (86.7%) 21 (13.3%) 3.15 (0.98-10.10)
+/+ 81 (68.6%) 37 (31.4%) 3.55 (1.57-7.99)
AP: 0.41 (-0.03-0.84)
94 (79.7%) 24 (20.3%) 5.22 (1.63-16.69)
AP: 0.31 (-0.22-0.84)
Smoke/+868 TC
-/- 68 (88.3%) 9 (11.7%) 1.0 (referent) 74 (96.1%) 3 (3.9%) 1.0 (referent)
-/+ 55 (90.2%) 6 (9.8%) 0.84 (0.29-2.43) 57 (93.4%) 4 (6.6%) 1.67 (0.40-7.02)
+/- 123 (82.6%) 26 (17.4%) 1.55 (0.70-3.44) 133 (89.3%) 16 (10.7%) 2.63 (0.80-8.63)
+/+ 82 (64.6%) 45 (35.4%) 3.98 (1.84-8.58)
AP: 0.66 (0.34-0.97)
98 (77.2%) 29 (22.8%) 6.37 (2.02-20.10)
AP: 0.49 (0.08-0.91)
’Negative’ and ‘positive’ values are presented as number (percentage). AP, the attributable proportion due to interaction; CI, confidence interval; OR, odds ratio;
TGFB1, transforming growth factor-beta-1.
Table 5 Replication study: association of the TGFB1+868
heterozygous genotype with ischaemic heart disease in
early rheumatoid arthritis patients stratified by ever
smoking
Ischemic heart disease
Smoke/+868 TC Negative Positive OR (95% CI)
-/- 25 (92.6%) 2 (7.4%) 1.0 (referent)
-/+ 38 (95.0%) 2 (5.0%) 0.66 (0.11-4.10)
+/- 69 (94.5%) 4 (5.5%) 0.66 (0.13-3.31)
+/+ 67 (81.7%) 15 (18.3%) 2.34 (0.57-9.61)
AP: 0.84 (0.14-1.53)
’Negative’ and ‘positive’ values are presented as number (percentage). AP, the
attributable proportion due to interaction; CI, confidence interval; OR, odds
ratio; TGFB1, transforming growth factor-beta-1.
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[29] showed slightly different results in a study that
included four TGFB1 SNPs (-509, +868, +913, and
+11929) and found an association in males only. This
study indicated that the primary MI-associated SNP was
-509, although both -509 and +868 were associated with
the disease in univariate analyses. A study from Japan
indicated an association of TGFB1+868 with MI in men
[26]. The above results suggest that the genetic locus
tagged by TGFB1-509 or +868 is important in suscept-
ibility to MI. Controversially, Cambien and colleagues
[25] showed that TGFB1+913, rather than -509, or +868
provided the strongest signal in relation to the associa-
tion with MI in Caucasian men from France or North-
ern Ireland.
It is not possible to say, on the basis of current data,
which (if any) of the SNPs examined has a causal rela-
tionship. However, the TGFB1-509 SNP, in the promo-
ter region of the gene, does not lie within a known
regulatory sequence and so is unlikely to play a role in
influencing the expression of TGF-b1. In contrast, the
TGFB1+868 SNP encodes an amino acid change (Leu/
Pro) in the signal peptide that is involved in export of
the pre-proprotein across membranes of the endoplas-
mic reticulum [51] and so this SNP may be associated
with the transportation or localization of TGF-b1 or
both. A transfection study in HeLa cells indicated that
the allele (C) encoding Pro 10 is associated with
increased rates of TGF-b1 secretion and that the +868
SNP alone has a functional effect independent of any
effect of the -509 polymorphism [52]. Previous studies
have also reported that serum TGF-b1 levels are higher
for Pro 10 homozygotes than Leu 10 homozygotes
[26,53].
In the present study, we found no association of the
TGFB1+868 or other SNPs with serum levels of TGF-
b1. Therefore, we speculate that the genetic association
seen with IHD/MI may be attributable to changes invol-
ving the processing or activation of TGF-b1 or both.
TGF-b1 is secreted in a latent complex in which mature
TGF-b1 dimers are associated with dimers of pro-pep-
tide, termed the latency-associated peptide (LAP) [54].
Growth factor activation requires the release of TGF-b1
from its LAP. One possible explanation for the hetero-
zygous association observed is that dimers of the pre-
proprotein formed by a combination of wild-type and
variant protein (+878 Leu/Pro ‘heterodimer’) have
altered functional characteristics compared with either
Leu/Leu or Pro/Pro homodimers. This involves the con-
cept of ‘molecular heterosis’, which occurs when the
heterozygote for a genetic polymorphism shows a signif-
icantly greater or lesser effect for a trait than the homo-
zygotes. Heterosis is believed to be common in humans
and can be gene-, phenotype-, gender-, and organ-speci-
fic [55].
Our data in patients with RA differed from those of
studies in general Caucasian populations in which it has
been suggested that the T allele at -509 or the C allele
at +868 or both were the risk alleles in a dominant [27]
or recessive [29] fashion. Data from Japan, however,
showed that the T allele at +868 was associated with MI
[26]. Interestingly, this is closer to our observation in
patients with RA, although in this case a combination of
Table 6 Multivariate stepwise logistic regression analysis of variables associated with ischaemic heart disease and
myocardial infarction
Ischemic heart disease (model 1a) Myocardial infarction (model 2b)
Variable Regression
coefficient
OR (95% CI) P
value
Variable Regression
coefficient
OR (95% CI) P
value
cSmoking+TGFB1
+868TC
1.012 2.75 (1.59-
4.75)
0.0003 cSmoking+TGFB1
+868TC
0.948 2.58 (1.33-
4.99)
0.0049
Age, per year 0.032 1.03 (1.01-
1.06)
0.023 RF-positive 0.655 1.93 (0.93-
3.99)
0.078
Male 0.744 2.10 (1.21-
3.65)
0.0080 Male 0.972 2.64 (1.37-
5.10)
0.0038
CRP ≥ 10 mg/L 1.030 2.80 (1.57-
5.01)
0.0005 CRP ≥ 10 mg/L 0.810 2.25 (1.11-
4.56)
0.025
Hypercholesterolemia 1.162 3.20 (1.69-
6.04)
0.0003 Hypercholesterolemia 1.196 3.31 (1.58-
6.91)
0.0014
dDiabetes 1.198 3.31 (1.36-
8.06)
0.0083 Hypertension 1.009 2.74 (1.36-
5.53)
0.0048
aPatients with ischemic heart disease (IHD) versus those without IHD; bpatients with myocardial infarction (MI) versus all non-MI patients; cpatients who have ever
smoked and carry the TGFB1+868 TC genotype in comparison with all remaining patients; dtype I or type II diabetes. Forward stepwise selection was used to
determine the variables most strongly associated with IHD and MI. Variables excluded by the stepwise procedure for IHD were disease duration, hypertension,
erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), body mass index (BMI), methotrexate treatment, steroid
treatment, erosive disease, and nodular disease. Variables excluded by the stepwise procedure for MI were age, disease duration, ESR, anti-CCP, BMI, diabetes,
methotrexate treatment, steroid treatment, erosive disease, and nodular disease. CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; RF, rheumatoid
factor; TGFB1, transforming growth factor-beta-1.
Chen et al. Arthritis Research & Therapy 2012, 14:R81
http://arthritis-research.com/content/14/2/R81
Page 8 of 11
the T and C alleles appears to provide the greatest risk.
The regulation and activation of TGF-b1 may be differ-
ent between the general population and individuals with
certain disease conditions (particularly, autoimmune dis-
ease in which TGF-b1 plays an important role), and the
potential for unique associations occurs in specific dis-
eases. Furthermore, additional risk factors associated
with IHD/MI in RA (for example, autoantibodies and
increased inflammation) may contribute to divergent
results between study populations.
It is particularly noteworthy that, in the absence of
smoking, the TGFB1+868 heterozygous genotype did
not confer an increased risk of IHD or MI. A gene-
smoking interaction thus appears essential for the
TGFB1 gene to play a role. The ‘excess’ risks for IHD
and MI directly attributed to this interaction were
approximately 65% and approximately 50%, respectively.
The mechanism involved is unknown, although it is
known that smoking affects cell-mediated and humoral
immune responses and is associated with both release
and inhibition of pro-inflammatory and anti-inflamma-
tory mediators [56]. Recently, in chronic obstructive pul-
monary disease, the oxidative effects of smoking
(reactive oxygen species) were found to be associated
with the activation of TGF-b [57]. Whether this effect
also exists in CVD remains to be investigated.
Several publications have suggested an association of
TGFB1 polymorphisms with CVD (mainly MI) [25-29],
but, as far as we are aware, none has investigated the
interaction between smoking and TGFB1 polymorph-
isms. It is interesting that, in some previous studies in
the general population [25,26,29], the association of
TGFB1 polymorphism with MI was observed among
males only. It is possible that the previously reported
lack of association among women is due to the lower
frequency of female smokers in the general population
and the naturally low incidence of MI for females. In
the patients with RA in this study, interaction of TGFB1
+868 with smoking has an effect in both genders (Table
S3 of Additional file 4).
There are several limitations to this study. First, the
number of patients with IHD or MI or both was rela-
tively small, although we were able to replicate the find-
ings in two separate RA cohorts with established and
early RA. Further studies, preferably with a larger num-
ber of cases, will be needed to confirm these results.
The second limitation is the possibility that some
patients with silent, non-full-thickness, or atypical MI
were missed. However, the MI incidence reported in
our RA population is comparable to that of other stu-
dies [5,12]. Another limitation was the absence of a con-
trol population, and so it was not possible to show
whether the association was RA-specific. Finally, the
study was cross-sectional in design, and so no time
course relationship was investigated, and it was possible
to assess only those subjects who had survived previous
events (for example, cardiac events and stroke).
Conclusions
We have demonstrated an association of polymorphism
in the TGFB1 gene with IHD and MI in RA. The stron-
gest association appears to be with the heterozygous
genotype of the +868 SNP and is dependent on an
interaction with smoking. The association did not
appear to be related to total serum levels of TGF-b1. If
these findings are confirmed in further studies, this
polymorphism may be useful for identifying those most
at risk of IHD and MI among patients who have RA
and who have smoked.
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Additional file 2: Table S1. Multivariate stepwise logistic regression
analysis of variables associated with ischaemic heart disease in patients
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Additional file 3: Table S2. Multivariate stepwise logistic regression
analysis of variables associated with ischaemic heart disease and
myocardial infarction in patients with established RA after inclusion of
smoking+VEGFA-2578A interaction term.
Additional file 4: Table S3. Association of TGFB1+868 heterozygous
genotype and ever having smoked with ischaemic heart disease and
myocardial infarction in RA patients stratified by sex.
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